Stephanie M Boyd1,2, Kristin L Riley3, Regan E Giesinger1,3, Patrick J McNamara4,5. 1. Neonatology Department, The Hospital for Sick Children, 555 University Avenue, Toronto, ON, M5G1X8, Canada. 2. Grace Centre for Newborn Intensive Care, Children's Hospital at Westmead, Cnr Hawkesbury Rd and Hainsworth St, Westmead, NSW, 2145, Australia. 3. Division of Neonatology, The University of Iowa, 200 Hawkins Dr, Iowa City, IA, 52242, USA. 4. Neonatology Department, The Hospital for Sick Children, 555 University Avenue, Toronto, ON, M5G1X8, Canada. patrick-mcnamara@uiowa.edu. 5. Division of Neonatology, The University of Iowa, 200 Hawkins Dr, Iowa City, IA, 52242, USA. patrick-mcnamara@uiowa.edu.
Abstract
OBJECTIVE: To determine the effect of vasopressin on arterial blood pressure in infants with neonatal hypertrophic obstructive cardiomyopathy (HOCM). STUDY DESIGN: Retrospective case study in Neonatal ICU involving six infants; five born to mothers with diabetes mellitus (mean gestational age 37.5 ± 0.9 weeks). Vasopressin infusion was started at a mean dose of 0.3 ± 0.2 mU/kg/min. RESULT: Initiation of vasopressin was followed by improved mean (p = 0.004), systolic (p = 0.028), and diastolic (p = 0.009) arterial pressure within 2 h. Heart rate (p = 0.025) and oxygen requirement (p = 0.021) also declined after initiation. Serum sodium declined initially and recovered by 72 h (p = 0.017). CONCLUSION: Although there is limited experience with vasopressin use in neonatal HOCM, our case series suggests it may be beneficial for improving systemic hypotension and stabilization of hemodynamics. The potential for hyponatremia is high, necessitating careful fluid/electrolyte management. A prospective randomized trial is necessary to confirm safety and efficacy of vasopressin treatment in neonatal HOCM.
OBJECTIVE: To determine the effect of vasopressin on arterial blood pressure in infants with neonatal hypertrophic obstructive cardiomyopathy (HOCM). STUDY DESIGN: Retrospective case study in Neonatal ICU involving six infants; five born to mothers with diabetes mellitus (mean gestational age 37.5 ± 0.9 weeks). Vasopressin infusion was started at a mean dose of 0.3 ± 0.2 mU/kg/min. RESULT: Initiation of vasopressin was followed by improved mean (p = 0.004), systolic (p = 0.028), and diastolic (p = 0.009) arterial pressure within 2 h. Heart rate (p = 0.025) and oxygen requirement (p = 0.021) also declined after initiation. Serum sodium declined initially and recovered by 72 h (p = 0.017). CONCLUSION: Although there is limited experience with vasopressin use in neonatal HOCM, our case series suggests it may be beneficial for improving systemic hypotension and stabilization of hemodynamics. The potential for hyponatremia is high, necessitating careful fluid/electrolyte management. A prospective randomized trial is necessary to confirm safety and efficacy of vasopressin treatment in neonatal HOCM.
Authors: A Franzese; G Valerio; N P Ciccarelli; G De Filippo; M P Iannucci; L Alfonsi; P Buono; V Farina Journal: Diabetes Care Date: 1997-04 Impact factor: 19.112
Authors: Jason F Goldberg; Carlos M Mery; Pamela S Griffiths; Dhaval R Parekh; Stephen E Welty; Ronald A Bronicki; Silvana Molossi Journal: Circulation Date: 2014-11-18 Impact factor: 29.690
Authors: Mohammed Al-Biltagi; Osama Abd Rab Elrasoul Tolba; Mohamed Ahmed Rowisha; Amal El-Sayed Mahfouz; Mona Ahmed Elewa Journal: Pediatr Cardiol Date: 2014-10-07 Impact factor: 1.655